Laddar...
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer. The anticancer activity of PARP inhibitors is based on the DNA repair vulnerability of many ovarian cancer cells, and multiple mechanisms of action o...
Sparad:
| I publikationen: | Ther Adv Med Oncol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
SAGE Publications
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5405993/ https://ncbi.nlm.nih.gov/pubmed/28491146 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016687254 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|